Real-life effectiveness and safety of salbutamol Steri-Neb™ vs. Ventolin Nebules® for exacerbations in patients with COPD: Historical cohort study.
Author | |
---|---|
Abstract |
:
Ventolin Nebules® (reference product; GlaxoSmithKline) was the first licensed nebulizer solution containing the rapid-onset, short-acting β2-agonist salbutamol. Salbutamol Steri-Neb™ (comparator; Teva Pharmaceuticals, Inc.) has the same chemical composition as the reference product. This study evaluated whether the effectiveness of the comparator is non-inferior to the reference product alongside concomitant medications during real-life clinical management of COPD exacerbations. Safety in terms of adverse events (AEs) was also examined. |
Year of Publication |
:
0
|
Journal |
:
PloS one
|
Volume |
:
13
|
Issue |
:
1
|
Number of Pages |
:
e0191404
|
Date Published |
:
2018
|
URL |
:
http://dx.plos.org/10.1371/journal.pone.0191404
|
DOI |
:
10.1371/journal.pone.0191404
|
Short Title |
:
PLoS One
|
Download citation |